首页 | 本学科首页   官方微博 | 高级检索  
     

中枢神经系统疾病治疗性抗体药物应用进展
引用本文:任华景,刘晓志,王志明,高健. 中枢神经系统疾病治疗性抗体药物应用进展[J]. 中国生物工程杂志, 2016, 36(9): 54-58. DOI: 10.13523/j.cb.20160907
作者姓名:任华景  刘晓志  王志明  高健
作者单位:华北制药集团新药研究开发有限责任公司 抗体药物研制国家重点实验室 石家庄 050015
基金项目:“十五”国家科技重大专项资助项目(2014ZX09201041)
摘    要:单克隆抗体药物是一种新兴的治疗药物,具有高选择性,被用于多种疾病的治疗,如肿瘤、免疫疾病等,也可以用于中枢神经系统疾病,如阿尔茨海默病、帕金森病、中风和脑肿瘤等。然而,因为血脑屏障低通透性,限制了抗体药物在中枢神经系统疾病治疗中的应用,在很多神经系统疾病临床试验中,抗体药物并没有取得预期效果。如今,人们利用血脑屏障上内源性转运蛋白介导,设计了可以通过血脑屏障的抗体药物。对通过血脑屏障治疗性抗体药物研发进展及其应用前景进行了综述。

关 键 词:中枢神经系统疾病  血脑屏障  单克隆抗体药物  
收稿时间:2016-02-29

Progression of Central Nervous System Disease Therapeutic Antibody Drug Application
REN Hua-jing,LIU Xiao-zhi,WANG Zhi-ming,GAO Jian. Progression of Central Nervous System Disease Therapeutic Antibody Drug Application[J]. China Biotechnology, 2016, 36(9): 54-58. DOI: 10.13523/j.cb.20160907
Authors:REN Hua-jing  LIU Xiao-zhi  WANG Zhi-ming  GAO Jian
Abstract:Monoclonal antibody drugs is a new drug with high selectivity, was used for the treatment of various diseases, such as cancer, autoimmune diseases, can also be used for central nervous system diseases, such as Alzheimer's disease, Parkinson, stroke and brain tumors. However, because of the low permeability of the blood-brain barrier, limiting the application of antibody drugs in the treatment of central nervous system diseases, in many nervous system diseases clinical trials, antibody drugs did not achieve the desired results. Nowadays, people use the endogenous transporter in blood-brain barrier, designed new antibody drugs. The progression of central nervous system disease therapeutic antibody drug development, and the application prospects are reviewed.
Keywords:Monoclonal antibody drugs  Central nervous system diseases  Blood brain barrier  
点击此处可从《中国生物工程杂志》浏览原始摘要信息
点击此处可从《中国生物工程杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号